MediSix Therapeutics, Inc. — Form D
MediSix Therapeutics, Inc. of BOSTON, MA, a company, filed a Form D exempt-offering notice with the SEC on 2021-04-13. The offering totals $22.0M, of which $15.0M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2021-04-13
- Form: D
- Accession: 0001713695-21-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $22.0M
- Amount sold: $15.0M
- Remaining: $7.0M
- Investors: 4
- Date of first sale: 2021-04-01
- Security types: debt
- Revenue range: Decline to Disclose
- SEC file number: 021-395539
Issuer
- Name: MediSix Therapeutics, Inc.
- CIK: 0001790058
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2019
- Address: 500 BOYLSTON STREET, SUITE 1380, BOSTON, MA, 02116
- Phone: 617-933-3770
Officers, directors & promoters (11)
| Name | Role | Location |
|---|
| Michael D Carusi | Director | BOSTON, MA |
| Kenneth D Noonan | Director | BOSTON, MA |
| Michael A Carusi | Director | Menlo Park, CA |
| MICHAEL CARUSI | Director | San Clemente, CA |
| Andrew R Bruce | Director | BOSTON, MA |
| Andrew R Bruce | Executive Officer | BOSTON, MA |
| William A Harrington | Director | BOSTON, MA |
| George A Poste | Director | BOSTON, MA |
| Kenneth D Noonan | Executive Officer | BOSTON, MA |
| George H Poste | Director | Singapore, U0 |
| Sarah D Lim | Executive Officer | Singapore, U0 |
Other filings by this issuer (2)
More